Patents Assigned to THE P.F. LABORATORIES
-
Patent number: 10407434Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: January 30, 2019Date of Patent: September 10, 2019Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10259819Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: September 29, 2017Date of Patent: April 16, 2019Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 9777011Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: March 2, 2016Date of Patent: October 3, 2017Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Publication number: 20160000776Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20160000719Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150374631Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: September 4, 2015Publication date: December 31, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150283130Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 3, 2015Publication date: October 8, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150273064Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 3, 2015Publication date: October 1, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265603Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265602Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265607Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265605Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265604Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150265606Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150182628Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: March 16, 2015Publication date: July 2, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150148319Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: January 30, 2015Publication date: May 28, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150147391Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: February 2, 2015Publication date: May 28, 2015Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130317051Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicants: Purdue Pharma L.P., PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
-
Publication number: 20130303494Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIESInventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130261145Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder